Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 4, pp. 341-351
Open Access | Times Cited: 1188

Showing 1-25 of 1188 citing articles:

Development of therapeutic antibodies for the treatment of diseases
Ruei‐Min Lu, Yu‐Chyi Hwang, I-Ju Liu, et al.
Journal of Biomedical Science (2020) Vol. 27, Iss. 1
Open Access | Times Cited: 1734
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang, Pengfei Shi, Gaichao Zhao, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1504
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju Vaddepally, Prakash Kharel, Ramesh Kumar Pandey, et al.
Cancers (2020) Vol. 12, Iss. 3, pp. 738-738
Open Access | Times Cited: 1041
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 822
Multimodal Analysis of Composition and Spatial Architecture in Human Squamous Cell Carcinoma
Andrew L. Ji, Adam J. Rubin, Kim Thrane, et al.
Cell (2020) Vol. 182, Iss. 2, pp. 497-514.e22
Open Access | Times Cited: 782
Immune Checkpoint Inhibitors in Cancer Therapy
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, et al.
Current Oncology (2022) Vol. 29, Iss. 5, pp. 3044-3060
Open Access | Times Cited: 721
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş, et al.
The Lancet (2021) Vol. 397, Iss. 10274, pp. 592-604
Closed Access | Times Cited: 631
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Ezra E.W. Cohen, R. Bryan Bell, Carlo Bifulco, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 589
Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
Charlene M. Fares, Eliezer M. Van Allen, Charles G. Drake, et al.
American Society of Clinical Oncology Educational Book (2019), Iss. 39, pp. 147-164
Closed Access | Times Cited: 558
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey, Baolin Zhang
The AAPS Journal (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 508
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang, Ming Chen, Hong Nie, et al.
Human Vaccines & Immunotherapeutics (2019) Vol. 15, Iss. 5, pp. 1111-1122
Open Access | Times Cited: 462
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Simona Sivori, Paola Vacca, Genny Del Zotto, et al.
Cellular and Molecular Immunology (2019) Vol. 16, Iss. 5, pp. 430-441
Open Access | Times Cited: 416
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial
Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 2, pp. 294-305
Open Access | Times Cited: 392
Cutaneous Squamous Cell Carcinoma
Abigail Waldman, Chrysalyne D. Schmults
Hematology/Oncology Clinics of North America (2018) Vol. 33, Iss. 1, pp. 1-12
Closed Access | Times Cited: 345
Survival with Cemiplimab in Recurrent Cervical Cancer
Krishnansu S. Tewari, Bradley J. Monk, Ignace Vergote, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 6, pp. 544-555
Open Access | Times Cited: 305
Organoid Models of Tumor Immunology
Kanako Yuki, Ning Cheng, Michitaka Nakano, et al.
Trends in Immunology (2020) Vol. 41, Iss. 8, pp. 652-664
Open Access | Times Cited: 287
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Adel Naimi, Rebar N. Mohammed, Ahmed Raji, et al.
Cell Communication and Signaling (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 278
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment
Alexander J. Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (2020) Vol. 128, pp. 83-102
Closed Access | Times Cited: 268
Update on Keratinocyte Carcinomas
Kishwer S. Nehal, Christopher K. Bichakjian
New England Journal of Medicine (2018) Vol. 379, Iss. 4, pp. 363-374
Closed Access | Times Cited: 261
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors
Harish Seethapathy, Sophia Zhao, Donald F. Chute, et al.
Clinical Journal of the American Society of Nephrology (2019) Vol. 14, Iss. 12, pp. 1692-1700
Open Access | Times Cited: 243
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)
Jean‐Jacques Grob, René González, Nicole Basset‐Séguin, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 25, pp. 2916-2925
Open Access | Times Cited: 226
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial
Alexander J. Stratigos, Aleksandar Sekulić, Ketty Peris, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 6, pp. 848-857
Open Access | Times Cited: 224
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
Neil D. Gross, David M. Miller, Nikhil I. Khushalani, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 17, pp. 1557-1568
Open Access | Times Cited: 206
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Thomas S. Uldrick, Priscila Gonçalves, Maher Abdul‐Hay, et al.
JAMA Oncology (2019) Vol. 5, Iss. 9, pp. 1332-1332
Open Access | Times Cited: 198
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention
Alexander J. Stratigos, Claus Garbe, Clio Dessinioti, et al.
European Journal of Cancer (2020) Vol. 128, pp. 60-82
Open Access | Times Cited: 198
Page 1 - Next Page

Scroll to top